Zymeworks Inc. (ZYME)
Fuera de horario:
Zymeworks Inc.
108 Patriot Drive
Suite A
Middletown, DE 19709
United States
(302) 274-8744
https://www.zymeworks.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 272
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Kenneth H. Galbraith C.A. | Chairman, CEO & Interim CFO | 1.04M | N/D | 1963 |
| Dr. Paul Moore Ph.D. | Chief Scientific Officer | 872.67k | N/D | 1968 |
| Mr. Mark Hollywood | Executive VP and Head of Technical & Manufacturing Operations | N/D | N/D | 1970 |
| Mr. Daniel Dex J.D., Ph.D. | Senior VP, Corporate Secretary & General Counsel | N/D | N/D | N/D |
| Diana Papove | Senior Manager of Corporate Communications | N/D | N/D | N/D |
| Dr. Lindsey Foulkes B.Sc., Ph.D. | Vice President of Corporate Development | N/D | N/D | N/D |
| Ms. Laura O'Connor | Vice President of Human Resources & DEI | N/D | N/D | N/D |
| Dr. Jeffrey Smith M.D. | Executive VP & Chief Medical Officer | N/D | N/D | N/D |
| Dr. Josemund Menezes MBBS | Managing Director of Early-Stage Development for Asia Pacific | N/D | N/D | N/D |
| Mr. John Fann Ph.D. | Senior Vice President of Process Sciences | N/D | N/D | N/D |
Descripción
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Gestión corporativa
La calificación ISS Governance QuickScore de Zymeworks Inc. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 9; Junta: 8; Derechos del accionista: 7; Compensación: 8.
